USFDA gives nod to Biocon Biologics’ biosimilar to treat Crohn’s disease

The biosimilar is approved for the treatment of Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis.

Biocon Q1 Result, Biocon Q1 Results 2024, Biocon Q1 Results 2024, Biocon Q1 Earning, Biocon Q1 Profit, Biocon Q1 Net Profit, Biocon Q1 FY25 Results 2024
Biocon Limited. (Image Credits: Reuters)

Biocon Biologics Ltd (BBL) on Sunday announced that the U.S. Food and Drug Administration (FDA) has approved YESINTEK (Ustekinumab-kfce), a biosimilar to the reference product, Stelara (Ustekinumab).

According to the company’s statement, YESINTEK, a monoclonal antibody, is approved for the treatment of Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis.

A company spokesperson stated that Biocon Biologics Ltd had previously notified the Stock Exchange on Feb 29, 2024, that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize YESINTEK in the United States of America no later than on February 22, 2025, upon approval from the U.S. FDA.

Get live Share Market updates, Stock Market Quotes, and the latest India News
This article was first uploaded on December one, twenty twenty-four, at forty-nine minutes past seven in the evening.
X